Associated Papers
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Comprehensive Molecular Docking and Molecular Dynamics Reveal Inhibitors of HER2 L755S, T798I, and T798M based on a Large Database of Curcumin Derivatives.
Gusrin MSD et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2026
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W et al.
International Journal of Molecular Medicine, 2025
The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population.
Erices JI et al.
Frontiers in Oncology, 2025
HER2 mutation as an emerging target in advanced breast cancer.
Bon G et al.
Cancer Science, 2024
Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells.
Zhang D et al.
Proteomics. Clinical Applications, 2024
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.
Marín A et al.
Cancer Research, 2023
Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations.
Tian H et al.
The Oncologist, 2023
Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.
Zhou S et al.
Journal of Molecular Modeling, 2022
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Chakravarty D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2022
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.
Shishido SN et al.
Npj Breast Cancer, 2022
Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L et al.
Annals of Medicine, 2021
Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases.
Ren Z et al.
Computational Biology and Chemistry, 2021
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Antitumour immunity regulated by aberrant ERBB family signalling.
Kumagai S et al.
Nature Reviews. Cancer, 2021
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT et al.
British Journal of Cancer, 2021
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review.
Qu Y et al.
Oncotargets and Therapy, 2021
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Smyth LM et al.
Cancer Discovery, 2020
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Chen Z et al.
Molecular Genetics & Genomic Medicine, 2020
Prevalence and role of HER2 mutations in cancer.
Cocco E et al.
Pharmacology & Therapeutics, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.
Uitdehaag JCM et al.
Molecular Cancer Therapeutics, 2019
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Nayar U et al.
Nature Genetics, 2019
Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB et al.
Cancer Discovery, 2019
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.
Cheng F et al.
Pharmacological Reviews, 2019
Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.
Jin J et al.
Frontiers in Oncology, 2019
Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab.
Zhang Y et al.
Oncotargets and Therapy, 2019
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T et al.
International Journal of Molecular Sciences, 2018
Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Christgen M et al.
Virchows Archiv : an International Journal of Pathology, 2018
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
Nagano M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Targeting ERBB2 mutations in solid tumors: biological and clinical implications.
Cousin S et al.
Journal of Hematology & Oncology, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Ma CX et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB et al.
Cancer Discovery, 2017
Activating HER2 mutations as emerging targets in multiple solid cancers.
Connell CM et al.
Esmo Open, 2017
Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
Chamberlin MD et al.
Journal of Cellular Biochemistry, 2016
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Sun Z et al.
Journal of Cellular and Molecular Medicine, 2015
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K et al.
The Journal of Biological Chemistry, 2011
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Zhou W et al.
Nature, 2009
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008